Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.23% | 13.69% | -51.07% | -63.31% | -120.80% |
| Total Depreciation and Amortization | 4.33% | 8.40% | -8.37% | -0.90% | -6.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.53% | -10.93% | 16.64% | -0.89% | 27.40% |
| Change in Net Operating Assets | 67.33% | -217.90% | 1,616.98% | 89.94% | -195.78% |
| Cash from Operations | 6.60% | -98.93% | -0.29% | -19.45% | -119.28% |
| Capital Expenditure | -459.77% | -52.16% | -75.76% | 14.29% | -1.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -78.46% | 183.92% | -759.32% | 106.22% | -1,176.05% |
| Cash from Investing | -82.21% | 183.02% | -771.44% | 106.12% | -1,189.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.73% | -8.68% | 2,859.65% | 463.18% | -59.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.73% | -8.68% | 2,859.65% | 463.18% | -59.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -161.33% | 8,911.99% | 104.55% | 89.53% | -218.06% |